Get the Stockscreener App
9.075
0.87%
-0.165
Fennec Pharmaceuticals Inc stock is traded at $9.075, with a volume of 39,991.
It is down -0.87% in the last 24 hours and up +4.33% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$9.24
Open:
$9.31
24h Volume:
39,991
Relative Volume:
0.51
Market Cap:
$252.83M
Revenue:
$21.25M
Net Income/Loss:
$-16.05M
P/E Ratio:
-14.88
EPS:
-0.61
Net Cash Flow:
$-17.14M
1W Performance:
+12.25%
1M Performance:
+4.33%
6M Performance:
+35.91%
1Y Performance:
+56.58%
1-Day Range:
$8.905
$9.42
1-Week Range:
$7.93
$9.42
52-Week Range:
$3.96
$9.42
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
9.09 | 227.85M | 21.25M | -16.05M | -17.14M | -0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.37 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.38 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.61 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
648.32 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.53 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
Why Fennec Pharmaceuticals Inc. is moving todayPortfolio Profit Report & AI Enhanced Trading Alerts - Newser
Applying chart zones and confluence areas to Fennec Pharmaceuticals Inc.Weekly Gains Summary & Community Verified Swing Trade Signals - Newser
Can trapped investors hope for a rebound in Fennec Pharmaceuticals Inc.Weekly Stock Report & Community Consensus Stock Picks - Newser
How to interpret RSI for Fennec Pharmaceuticals Inc. stockWeekly Stock Recap & Weekly Setup with ROI Potential - Newser
Will Fennec Pharmaceuticals Inc. stock go up soon2025 Buyback Activity & Expert Approved Trade Ideas - Newser
Why Fennec Pharmaceuticals Inc. stock attracts strong analyst attention [2025 Historical Comparison]Community Trade Idea Sharing - Newser
How to manage a losing position in Fennec Pharmaceuticals Inc.Free Entry Points For Growing Stocks - Newser
Fennec Pharmaceuticals Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Measuring Fennec Pharmaceuticals Inc.’s beta against major indicesCapital Secure Pattern Signal Analysis Sheet - Newser
Stocks In Play: Fennec Pharmaceuticals Inc. - Barchart.com
Fennec Pharmaceuticals to Announce Q2 2025 Financial Results - TipRanks
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025 - The Manila Times
Fennec Pharmaceuticals to announce Q2 2025 financial results on Aug. 14. - AInvest
Fennec Pharmaceuticals Inc. stock outlook for YEAREarly Entry Ideas with Momentum Potential - Newser
Real time pattern detection on Fennec Pharmaceuticals Inc. stockDividend Strategy Summary With 10-Year Outlook - Newser
Adherex Technologies (FENC) to Release Earnings on Tuesday - Defense World
What makes Fennec Pharmaceuticals Inc. stock price move sharplyShort-Term Swing Opportunity Summary Sheet - Newser
Fennec Pharmaceuticals FENC Q2 2025 Earnings Preview Downside Concerns Amid Product Vulnerability Issues - AInvest
How Fennec Pharmaceuticals Inc. stock performs during market volatilityLong-Term Signal Tracking and Profit Summary - Newser
Full technical analysis of Fennec Pharmaceuticals Inc. stockPredictive Model for Intraday Swing Forecast - Newser
Anterix Holds Virtual Annual Stockholders Meeting - The Globe and Mail
Paymentus Holdings: Strong Growth and Raised Guidance - The Globe and Mail
Using data filters to optimize entry into Fennec Pharmaceuticals Inc.Rapid Trade Forecast Based on Indicators - Newser
Evaluating Fennec Pharmaceuticals Inc. with trendline analysisCapital Protection Strategy With Risk Analysis - Newser
Adherex Technologies (NASDAQ:FENC) Trading Up 6.1% – Still a Buy? - Defense World
Is it too late to sell Fennec Pharmaceuticals Inc.Summary of Long-Term Buy Zone Stocks - Newser
Using economic indicators to assess Fennec Pharmaceuticals Inc. potentialFree Early Entry Tips With Low Risk Zone - Newser
What is the dividend policy of Fennec Pharmaceuticals Inc. stockCapitalize on market momentum for maximum gains - Jammu Links News
What institutional investors are buying Fennec Pharmaceuticals Inc. stockSuperior portfolio returns - Jammu Links News
How does Fennec Pharmaceuticals Inc. compare to its industry peersExceptional profit potential - Jammu Links News
Is Fennec Pharmaceuticals Inc. a good long term investmentDiscover undervalued opportunities early - Jammu Links News
Is it the right time to buy Fennec Pharmaceuticals Inc. stockDiscover undervalued stocks ready to soar - Jammu Links News
What are the technical indicators suggesting about Fennec Pharmaceuticals Inc.Tremendous growth opportunities - Jammu Links News
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):